FLT1 D3 Human, His

Vascular Endothelial Growth Factor Receptor-1 D3 Human Recombinant, His Tag
Cat. No.
BT20949
Source
Insect Cells.
Synonyms
FLT-1, FLT1, Tyrosine-protein kinase receptor FLT, Flt-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1, VEGFR-1.
Appearance
Sterile Filtered clear solution.
Purity
Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

FLT1 D1-3 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide containing 298 amino acids fragment (31-328) and having a molecular mass of 38.16kDa. The receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF.
The FLT1 is purified by proprietary chromatographic techniques.

Product Specs

Introduction
Three distinct vascular endothelial growth factor (VEGF) receptors, which belong to the receptor tyrosine kinases (RTKs) family, are expressed by endothelial cells. These receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4), exhibit almost exclusive expression on endothelial cells. However, VEGFR-1 is also found on monocytes, dendritic cells, and trophoblast cells. The flt-1 gene was first characterized in 1990. The receptor structure comprises seven immunoglobulin-like extracellular domains, a single transmembrane region, and an intracellular split tyrosine kinase domain. In comparison to VEGFR-2, the Flt-1 receptor demonstrates a higher affinity for VEGF but weaker signaling activity, suggesting that VEGFR-1 does not induce endothelial cell proliferation but rather mediates signals for differentiation. Notably, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1), produced by alternative splicing of the flt-1 mRNA, was identified in HUVE supernatants in 1996. While the biological functions of sVEGFR-1 remain unclear, it appears to act as an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.
Description
Recombinant Human FLT1 D1-3, produced in baculovirus, is a monomeric, glycosylated polypeptide encompassing amino acids 31-328. This fragment, with a molecular weight of 38.16 kDa, consists of the first three extracellular domains of the FLT1 receptor, which are sufficient for VEGF binding. The purification of FLT1 is achieved through proprietary chromatographic methods.
Physical Appearance
A clear solution that has undergone sterile filtration.
Formulation
FLT1 His is supplied at a concentration of 0.96 mg/ml in a buffer consisting of 25 mM Sodium Acetate (pH 4.8) and 50% glycerol.
Stability
For optimal storage, keep the product at 4°C if the entire vial will be consumed within 2-4 weeks. For extended storage, freeze the product at -20°C. It is crucial to avoid repeated freeze-thaw cycles.
Purity
The purity of the product exceeds 95.0%, as determined by the following methods: (a) Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis and (b) Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis.
Synonyms
FLT-1, FLT1, Tyrosine-protein kinase receptor FLT, Flt-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1, VEGFR-1.
Source
Insect Cells.

Product Science Overview

Introduction

Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1), also known as Fms-like tyrosine kinase-1 (Flt-1), is a receptor tyrosine kinase that plays a crucial role in angiogenesis and vasculogenesis. It is part of the VEGF receptor family, which includes VEGFR-1, VEGFR-2, and VEGFR-3. These receptors are activated by binding to their respective ligands, the Vascular Endothelial Growth Factors (VEGFs), which are key regulators of blood vessel formation.

Structure and Function

VEGFR-1 consists of an extracellular domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. The extracellular domain is composed of seven immunoglobulin-like (Ig-like) domains, with the third domain (D3) being critical for ligand binding. The D3 domain of VEGFR-1 is responsible for high-affinity binding to VEGF-A, VEGF-B, and placental growth factor (PlGF).

VEGFR-1 acts primarily as a decoy receptor, sequestering VEGF ligands and preventing them from binding to VEGFR-2, which is the main mediator of angiogenic signaling. By modulating the availability of VEGF ligands, VEGFR-1 regulates angiogenesis and vascular permeability.

Recombinant VEGFR-1 D3

Recombinant VEGFR-1 D3 (Human, His Tag) is a truncated form of the receptor that includes the third Ig-like domain fused to a polyhistidine (His) tag. The His tag facilitates purification and detection of the recombinant protein using nickel affinity chromatography and anti-His antibodies, respectively.

Expression and Purification

The recombinant VEGFR-1 D3 is typically expressed in bacterial or mammalian expression systems. In bacterial systems, the gene encoding the D3 domain is cloned into an expression vector and transformed into Escherichia coli (E. coli) cells. The cells are then induced to produce the recombinant protein, which is subsequently purified using nickel affinity chromatography. In mammalian systems, the gene is transfected into Chinese hamster ovary (CHO) cells or other suitable cell lines, and the recombinant protein is secreted into the culture medium for purification.

Applications

Recombinant VEGFR-1 D3 is used in various research applications, including:

  • Binding Studies: Investigating the interaction between VEGFR-1 and its ligands.
  • Inhibition Assays: Evaluating the efficacy of potential inhibitors targeting VEGFR-1.
  • Structural Studies: Analyzing the structure of the VEGFR-1 D3 domain to understand its binding mechanism.
  • Therapeutic Development: Developing anti-angiogenic therapies for diseases such as cancer, where VEGF signaling plays a critical role in tumor growth and metastasis.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.